Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these findings, a clear link has yet to be established, and much of the evidence remains ...

This study is significant as it explores a potential new treatment option for diabetic retinopathy, a leading cause of blindness. The intervention tested was EYP-1901, a Tyrosine Kinase Inhibitor, ...

British number one blind golfer Billy McAllister recalls his journey in the sport after completely losing his eyesight in ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...

The Sultanate of Oman is the third country worldwide to implement this project, confirming its commitment to technological ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight increase in new diabetic retinopathy cases but fewer severe eye complications, ...

Empowering choice in the pharmacological management of type 2 diabetes One in nine people worldwide lives with diabetes, with 90% affected by type 2 diabetes.1 Despite ongoing advances in therapy and ...